Amyotrophic lateral sclerosis (ALS) is a disease that destroys the nerves necessary for movement. About 30,000 people in the ...

Amyotrophic lateral sclerosis (ALS) is a disease that destroys the nerves necessary for movement. About 30,000 people in the United States are affected, and doctors still don't know what causes it.

Advocates for patients with amyotrophic lateral sclerosis — a fatal condition known as Lou Gehrig’s disease — urged lawmakers ...

Treatment with regulatory T-cells, known as Tregs, was well tolerated and seemed to reduce disease activity in a small ...

The FDA cleared the launch of a Phase 1 clinical trial to test cell therapy XS-228 in people with amyotrophic lateral ...

While a comprehensive cure-all to these neurological conditions is unlikely, scientists are making headway into understanding their fundamental characteristics with the hope of preventing or ...

Every year roughly 1,000 Canadians are diagnosed with amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease). Some 4,000 Canadians are currently living with the disease. There are few ...

levels as an indicator of clinical progression and survival in amyotrophic lateral sclerosis (ALS). Methods A cross-sectional study involving 136 clinically heterogeneous patients with ALS and 104 ...

Actor Eric Dane, known for Grey's Anatomy and Euphoria, has revealed his diagnosis with Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease. ALS affects nerve cells and muscle ...

Oral edaravone for patients with amyotrophic lateral sclerosis (ALS) is safe through a total of 144 weeks with no new safety signals observed. Among patients with amyotrophic lateral sclerosis ...

Scientists say an extract of the ancient medicinal plant a shwagandha has shown promise as a potential treatment to slow the symptoms of amyotrophic lateral sclerosis, also known as motor neurone ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib ...